Go homepage(回首页)
Upload pictures (上传图片)
Write articles (发文字帖)

The author:(作者)归海一刀
published in(发表于) 2014/2/11 10:04:36
National has H7N9 over 180 cases confirmed this year， 47 people died

Original title: H7N9 avian flu confirmed this year in mainland China was declared over more than 180 cases of vaccine clinical trials

International online news (reporters Pan Ying Song Daoyu interns): human infection with H7N9 avian influenza is now making a comeback this year, more than 180 confirmed cases have been reported in mainland China, killed 47 people, incidence more than last year. There are now multiple H7N9 reporting clinical trials of vaccines, State 10th that will facilitate vaccine research and development and commercialization, according to disease development of vaccines for approval listed.

Last March, first human infection H7N9 avian influenza cases reported in mainland China. Subsequently, the fast growth of the epidemic, March-July of last year, more than 130 cases were reported, including 45 deaths. "Disappear" after about 3 months, last December H7N9 comeback, now Jiangsu, Zhejiang and other coastal provinces H7N9 reported new cases almost daily, national H7N9 daily on the growth of 5 to 7 cases of confirmed cases.

Reporters from China's Center for disease control to get the latest data show that 1 to February of this year, to reach more than 180 cases of human infection with avian influenza virus, which killed 47 people. National health family planning Commission, spokesman for Yao Hongwen introduced said, future a time, also may occurred more of distributed cases: "on recently H7N9 outbreak of study, integrated analysis recently outbreak related of disease original learn, and epidemic learn and clinical performance, of monitoring information, expert Institute sentenced think, currently people infection H7N9 avian influenza outbreak of features is not occurred obviously changes, cases still to distributed mainly, monitoring is not found virus occurred has public health of variation, and virus of spread way still is by poultry to people. Experts predict that China's Mainland in the near future may be sporadic cases of human infection H7N9 avian influenza continue to occur. ”

At present, China has declared several H7N9 vaccine clinical trials. A few days ago, and reproduction made by the Shanghai new infectious diseases Institute news release, whose research group has succeeded in developing DNA vaccines against the virus H7N9, the vaccine has entered the stage of clinical trials reporting. But this is not the only Chinese entered the stage of clinical trials reporting vaccine. Earlier, at least Beijing xinghe hualan biological respectively, the two companies own H7N9 vaccine to the State food and Drug Administration formally proposed clinical trial applications. State food and Drug Administration has yet to reply on these applications.

National health family planning Commission spokesman Yao Hongwen today reported that Zhejiang, a research team has successfully developed H7N9 avian flu vaccine seed strain, and verification by authorities. Related departments will further promote the vaccine research and development and the outcome of conversion, according to the disease development, advance approval of the vaccine market. "In 2013, Zhejiang University in isolating the get a H7N9 avian influenza virus strains on the basis of successfully developed H7N9 avian flu vaccine seed strains, vaccine seed strain of the virus has passed all test. Defense control unit will further promote the work mechanism of vaccine research and development and the outcome of conversion, and depending on developments in the outbreak of a vaccine approval and listing preparations. ”

It is understood that the vaccine clinical trials reporting does not mean that the vaccine will soon be listed, from preclinical research to clinical trials of new vaccines to the listing of approved, subject to prudent audit links, typically takes several years of time. This length of time, on the one hand depends on whether the vaccine development process and technology solutions offers one hand depends mainly on the epidemic situation of the epidemic development situation and Government judged. Early in 2009, the swine flu pandemic, Chinese authorities launched a special approval of the vaccine program, making influenza a vaccine development period is shortened to 87 days.

Live bird markets have been considered the main place the H7N9 avian flu vaccine. Controlling H7N9 outbreak last year, China had shut down the live poultry markets, as rates fall, many live bird markets reopen. Chinese Center for disease control viral disease control and prevention, said Shu Yuelong, Deputy Director, national influenza centre Director, currently H7N9 avian influenza transmission continues to be dominated by human contact with birds infected, while meeting people during the Spring Festival, many opportunities to uses poultry is the root cause of the current cases have continued to occur. "The most important thing is to change the current patterns of backyard and sold live poultry market, be sure to turn it into a large-scale farming. As you can see, H7N9 avian influenza virus in all intensive farming not detected vulnerabilities. We must gradually transformed to the intensive farming combined with modern marketing methods, is the popular saying of chilled chickens upon way. This change also required a great deal of investment, reducing the impact of infectious diseases on the national economy in the long term. ”

　　原标题：中国内地今年H7N9禽流感确诊超过180例 多个疫苗正申报临床试验

　　国际在线消息(记者 潘莹 实习生 宋道玉)：人感染H7N9禽流感目前正在卷土重来，今年以来中国内地已经报告了超过180个确诊病例，死亡47人，发病数超过去年。目前已有多个H7N9疫苗申报临床试验，中国官方10日表示，将推动疫苗研发和成果转化，根据疫情发展推进疫苗审批上市。

　　去年三月底，中国内地首次报告人感染H7N9禽流感病例。随后，疫情发展较快，去年3－7月间，共报告病例130多例，其中45例死亡。在“销声匿迹”约3个月后，去年12月H7N9卷土重来，目前江苏、浙江等东南沿海省份几乎每天都报告H7N9新发病例，全国H7N9确诊病例每天以5至7例规模增长。

　　记者从中国疾控中心获得最新数据显示，今年1至2月份，人感染禽流感病毒的病例达到180多例，其中死亡47人。国家卫生计生委新闻发言人姚宏文介绍说，今后一段时间，还可能发生更多的散发病例：“关于近期H7N9疫情的研判，综合分析近期疫情相关的病原学、流行病学和临床表现等的监测信息，专家研判认为，目前人感染H7N9禽流感疫情的特点未发生明显变化，病例仍以散发为主，监测未发现病毒发生有公共卫生的变异、病毒的传播途径仍然是由禽到人。专家预测，近期我国内地可能继续出现人感染H7N9禽流感的散发病例。”

　　目前，中国国内已有数个H7N9疫苗申报临床试验。几天前，上海市新发与再现传染病研究所也发布消息称，他们的课题组已成功研制出针对病毒H7N9的基因疫苗，该疫苗已进入临床试验申报阶段。但这并非中国唯一进入临床试验申报阶段的疫苗。此前，至少还有北京科兴和华兰生物两家公司分别就自己研制的H7N9疫苗向国家食品药品监督管理总局正式提出临床试验申请。国家食药总局尚未就这些申请作出批复。

　　国家卫生计生委新闻发言人姚宏文今天通报说，浙江一个科研团队也成功研发出H7N9禽流感疫苗的种子株，并通过权威部门检定。相关部门将进一步推进疫苗研发及成果的转化，根据疫情发展，推进疫苗的审批上市。“2013年浙江大学在成功分离获得一株H7N9禽流感病毒的基础上，成功研制出H7N9禽流感疫苗的种子株，该病毒的疫苗种子株已经通过全部检定。联防联控工作机制的相关单位将进一步推进疫苗研发及成果的转化，并根据疫情的发展情况做好疫苗的审批、上市的准备。”

　　据了解，但疫苗临床试验申报并不意味着疫苗上市在即，新疫苗从临床前研究到临床试验再到获批上市，还须经过谨慎的审核环节，一般还需要数年的时间。而这个时间的长短，一方面取决于疫苗研制的工艺和技术方案是否完备；另一方面则主要取决于疫情的发展形势以及政府对疫情形势的判断。早在2009年，面对甲型H1N1流感疫情，中国相关部门启动了疫苗特别审批程序，使得甲型H1N1疫苗研制周期缩短到了87天。

　　活禽市场一直被认为是H7N9禽流感疫苗的最主要传播场所。去年为了防控H7N9疫情，中国曾关闭了活禽市场，随着发病率的下降，许多活禽市场重新开启。中国疾病控制中心病毒病预防控制所副所长、国家流感中心主任舒跃龙说，目前H7N9禽流感的传播途径仍然是以人接触禽感染为主，而春节期间人接触、使用禽的机会较多是目前病例继续发生的根本原因。“最重要的是改变目前的散养和活禽市场销售的模式，一定要把它变成一种规模化的养殖。大家可以看到，这次H7N9禽流感病毒在所有规模化养殖场没有监测到漏洞。我们要逐步转化到规模化养殖再加上现代化的销售方式，就是通俗说的冰鲜鸡的销售方式。这个改变也需要很大的投入，长远来看可以降低传染病对国民经济的影响。”

赞